Heres what we do know from the few human reports available, and why they offer limited reassurance: Phase I trial (unpublished): In 2015, a formal Phase I trial on 42 healthy volunteers was initiated to assess BPC-157s safety and pharmacokinetics
Lose 14-15% of your body weight* *In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
The relationship between excitotoxicity and oxidative stress in the central nervous system
Tabe Y, Hatanaka Y, Ruvolo P, Miida T, Kornblau S, Andreeff M , Konopleva M
p = 0.004), IL-12p70 ( = 0.737
M.) 431442 (Springer, 2000)